Yan Leyfman: Neoadjuvant combination ICI reshapes CD8+ T cell responses in head and neck cancer
Yan Leyfman, Co-founder and executive director of MedNews Week, posted on LinkedIn about recent paper by Housaiyin Li et al., titled “Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies” published on Cancer Cell.
Authors: Housaiyin Li, Dan P. Zandberg, Aditi Kulkarni, Simion I. Chiosea, Patricia M. Santos, Brian R. Isett, Marion Joy, Gabriel L. Sica, Kevin J. Contrera, Curtis M. Tatsuoka, Matthias Brand, Umamaheswar Duvvuri, Seungwon Kim, Mark Kubik, Shaum Sridharan, Fei Tu, Jie Chen, Tullia C. Bruno, Dario A.A. Vignali, Anthony R. Cillo, Riyue Bao, Jing Hong Wang, Lazar Vujanovic, Robert L. Ferris.
“New findings from Dr. Fobert Ferris and team of UNC Lineberger Comprehensive Cancer Center reveal how neoadjuvant combination ICI reshapes CD8+ T cell responses in head and neck cancer!
Key Highlights:
- Stronger Tumor Rejection with combo ICI vs. monotherapy.
- CD8+ T Cell States at Baseline predict response.
- Nivo+Ipi expands effector and resident memory T cells (TEM/TRM) in responders.
- Nivo+Rela reprograms IFN-I responsive CD8+ T cells into TEM/TRM.
- LAG-3 blockade enhances TCR sharing and diversity, unlike CTLA-4.
Takeaway: Different ICI combinations drive distinct CD8+ T cell dynamics, shaping immune responses for better outcomes!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023